Publications by authors named "D L Sarid"
Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes.
Objectives: The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures.
Article Synopsis
- * PectaSol-Modified citrus pectin (P-MCP), an FDA-recognized safe food supplement, has shown promise in improving prostate-specific antigen doubling time (PSADT) in 75% of patients after 6 months of treatment.
- * In a second phase of a study lasting 12 months, 85% of patients maintained a long-term response to P-MCP, with significant improvements in PSA levels and safety, confirming its potential effectiveness and safety for BRPC-M0 patients.
Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival.
View Article and Find Full Text PDFAlthough prostate-specific membrane antigen (PSMA) PET/CT has been shown valuable for staging biopsy-proven [B(+)] high-risk prostate cancer, elderly patients are occasionally referred for PSMA PET/CT without a preimaging confirming biopsy [B(-)]. The current study evaluated the rate, clinical characteristics, and PET-based stage of elderly B(-) patients and explored whether biopsy status affects therapeutic approach. One hundred consecutive patients at least 80 y old who underwent staging Ga-PSMA-11 PET/CT were included.
View Article and Find Full Text PDFIntroduction: Current guidelines do not support the use of pretreatment imaging in patients with favorable intermediate-risk prostate cancer. Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is more accurate than conventional imaging for preoperative staging. We aimed to evaluate whether pretreatment Ga-PSMA PET/CT is beneficial for identifying pathological lymph node involvement (LNI) and adverse pathology among patients with favorable intermediate-risk prostate cancer.
View Article and Find Full Text PDF